Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2025)
15 slides from Enveric Biosciences's investor presentation, August 2025
Slide 1: Corporate Presentation
:ENVB CORPORATE PRESENTATION Q1 2025 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Next Generation Mental Health
Next Generation TM Mental Health
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD WIDESPREAD LOW EFFICACY 65 million in the US 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Source: (NIMH) (SingleCare) (World Heal
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neuroplasticity in the PFC, which restores This modulates the fi
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: • Current psychedelic neuroplastogens in clinical trials cause hallucinations in the patient • Can require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling • Often require psychotherapy as part of the treat
Slide 7: EB-003: Non-Hallucinogenic, Orally Available, Neuroplastogenic DMT Analog
EB-003: Non-Hallucinogenic, Orally Available, Neuroplastogenic DMT Analog • Synthesized library of DMT analogs • Assessed preclinical properties • In vitro target engagement • In vivo head twitch response in mice • In vitro neuronal development DMT N,N-dimethyltryptamine • In vitro and in vivo pharm
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic Targeted Benefits* Antidepressants Neuroplastogens For EB-003 Immediate efficacy Low side effects Treatment in-clinic not required Large patient population Induces neuroplasticity in brain * To be proven in human clinical trials :ENVB
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits • Reduced hallucination profile, treatment in clinic not required • Lower side effects • Rapid acting • Orally bioavailable • Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient 2025 2026
Slide 10: EVM401: Lead Discovery Underway
EVM401: Lead Discovery Underway Overview • Novel phenylalkylamines and indolethylamines • Anticipated to interact with key brain receptors associated with mental health disorders and addiction. Potential Applications: • Early analysis suggests EVM401 compounds could target: • Substance use disorders
Slide 11: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Predicted Neuroplastogen Antidepressant Market: EB-003: A Breakthrough Market: Neuroplastogen $20 Billion $35.4 Billion Neuroplastogen drug market anticipated by 2030 Leading Neuroplastogen Source: Cohe
Slide 12: Product Pipeline
Product Pipeline Discovery Preclinical IND Phase 1 Partner / Licensee Available for Partnering Partner EB-003 & EVM301 Series Available Neuroplastogens EVM401 Series Available Neuroplastogens Out-Licensed Licensee EB-002 & EVM201 Series MycoMedica Life Sciences Psilocin Prodrugs Topical Candidates f
Slide 13: Management
Management Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D. Chief Executive Officer Board Chair Scientific Advisor & Director George Kegler Stephen M. Stahl, M.D. Director, Chair of the Audit Committee Scientific Advisor Kevin Coveney, C
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate • EB-003 is one of the leading neuroplastogen drug candidates • Anticipate filing IND in Q1 of 2026 and Phase I start in Q2 2026 New Drug Class Market Opportunity • A $35.4 billion market awaits
Slide 15: Enveric Biosciences - Enveric.com
Nasdag :ENVB ENVERIG AM trentar fearen= Mental Health™ BIOSCIENCES Enveric.com
Enveric Biosciences — Investor Presentation (August 2025) on 6ix